Osiris Therapeutics, Inc. (OSIR) Announces Expansion Of The Leadership Team

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, is pleased to announce the expansion of the management team with the appointment of Adrian Mollo as General Counsel and Dr. Jon Hopper as Chief Medical Officer, both reporting to Lode Debrabandere, Ph.D., President and Chief Executive Officer. Gregory Law also recently joined the Osiris management team as Vice President of Finance and Principal Accounting Officer, reporting to Philip Jacoby, Chief Financial Officer.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.